{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T04:08:04Z","timestamp":1775275684018,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2011,9,3]],"date-time":"2011-09-03T00:00:00Z","timestamp":1315008000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tumor Biol."],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1007\/s13277-011-0222-1","type":"journal-article","created":{"date-parts":[[2011,9,6]],"date-time":"2011-09-06T18:11:22Z","timestamp":1315332682000},"page":"1191-1197","source":"Crossref","is-referenced-by-count":12,"title":["Transcription suppression of SARI (suppressor of AP-1, regulated by IFN) by BCR-ABL in human leukemia cells"],"prefix":"10.1007","volume":"32","author":[{"given":"Qing","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoqing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,9,3]]},"reference":[{"key":"222_CR1","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","volume":"96","author":"MW Deininger","year":"2000","unstructured":"Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000;96:3343\u201356.","journal-title":"Blood"},{"key":"222_CR2","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","volume":"113","author":"A Quintas-Cardama","year":"2009","unstructured":"Quintas-Cardama A, Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood. 2009;113:1619\u201330.","journal-title":"Blood"},{"key":"222_CR3","doi-asserted-by":"crossref","first-page":"250","DOI":"10.4161\/cc.10.2.14537","volume":"10","author":"A Hochhaus","year":"2011","unstructured":"Hochhaus A, La Rosee P, Muller MC, Ernst T, Cross NC. Impact of BCR-ABL mutations on patients with chronic myeloid leukemia. Cell Cycle. 2011;10:250\u201360.","journal-title":"Cell Cycle"},{"key":"222_CR4","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/sj.leu.2403241","volume":"18","author":"LS Steelman","year":"2004","unstructured":"Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE, McCubrey JA. JAK\/STAT, Raf\/MEK\/ERK, PI3K\/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia. 2004;18:189\u2013218.","journal-title":"Leukemia"},{"key":"222_CR5","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031\u20137.","journal-title":"N Engl J Med"},{"key":"222_CR6","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.canlet.2010.10.018","volume":"300","author":"M Breccia","year":"2011","unstructured":"Breccia M, Efficace F, Alimena G. Imatinib treatment in chronic myelogenous leukemia: what have we learned so far? Cancer Lett. 2011;300:115\u201321.","journal-title":"Cancer Lett"},{"key":"222_CR7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/leu.2010.238","volume":"25","author":"D Bixby","year":"2011","unstructured":"Bixby D, Talpaz M. Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia. Leukemia. 2011;25:7\u201322.","journal-title":"Leukemia"},{"key":"222_CR8","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.beha.2008.09.001","volume":"21","author":"JC Wong","year":"2008","unstructured":"Wong JC, Le Beau MM, Shannon K. Tumor suppressor gene inactivation in myeloid malignancies. Best Pract Res Clin Haematol. 2008;21:601\u201314.","journal-title":"Best Pract Res Clin Haematol"},{"key":"222_CR9","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2217\/14796694.5.2.245","volume":"5","author":"C Britschgi","year":"2009","unstructured":"Britschgi C, Fey MF. Tumor suppressor genes in myeloid differentiation and leukemogenesis. Future Oncol. 2009;5:245\u201357.","journal-title":"Future Oncol"},{"key":"222_CR10","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/nature09999","volume":"473","author":"A Klinakis","year":"2011","unstructured":"Klinakis A, Lobry C, Abdel-Wahab O, Oh P, Haeno H, Buonamici S, et al. A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. Nature. 2011;473:230\u20133.","journal-title":"Nature"},{"key":"222_CR11","doi-asserted-by":"crossref","first-page":"20906","DOI":"10.1073\/pnas.0807975106","volume":"105","author":"ZZ Su","year":"2008","unstructured":"Su ZZ, Lee SG, Emdad L, Lebdeva IV, Gupta P, Valerie K, et al. Cloning and characterization of SARI (suppressor of AP-1, regulated by IFN). Proc Natl Acad Sci USA. 2008;105:20906\u201311.","journal-title":"Proc Natl Acad Sci USA"},{"key":"222_CR12","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.exer.2008.09.008","volume":"87","author":"L Guo","year":"2008","unstructured":"Guo L, Yu W, Li X, Zhao G, Liang J, He P, et al. Targeting of integrin-linked kinase with a small interfering RNA suppresses progression of experimental proliferative vitreoretinopathy. Exp Eye Res. 2008;87:551\u201360.","journal-title":"Exp Eye Res"},{"key":"222_CR13","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1182\/blood-2008-03-147033","volume":"112","author":"B Huang","year":"2008","unstructured":"Huang B, Lei Z, Zhang GM, Li D, Song C, Li B, et al. SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironment. Blood. 2008;112:1269\u201379.","journal-title":"Blood"},{"key":"222_CR14","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1182\/blood.V95.3.731.003k28_731_737","volume":"95","author":"C Cobaleda","year":"2000","unstructured":"Cobaleda C, Sanchez-Garcia I. In vivo inhibition by a site-specific catalytic RNA subunit of RNase P designed against the BCR-ABL oncogenic products: a novel approach for cancer treatment. Blood. 2000;95:731\u20137.","journal-title":"Blood"},{"key":"222_CR15","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1016\/S0301-472X(99)00096-X","volume":"27","author":"F Dazzi","year":"1999","unstructured":"Dazzi F, Szydlo RM, Goldman JM. Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant: where we now stand. Exp Hematol. 1999;27:1477\u201386.","journal-title":"Exp Hematol"},{"key":"222_CR16","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1182\/blood.V95.5.1781.005k46_1781_1787","volume":"95","author":"J Pinilla-Ibarz","year":"2000","unstructured":"Pinilla-Ibarz J, Cathcart K, Korontsvit T, Soignet S, Bocchia M, Caggiano J, et al. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood. 2000;95:1781\u20137.","journal-title":"Blood"},{"key":"222_CR17","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","volume":"105","author":"M Deininger","year":"2005","unstructured":"Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood. 2005;105:2640\u201353.","journal-title":"Blood"},{"key":"222_CR18","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1126\/science.289.5486.1938","volume":"289","author":"T Schindler","year":"2000","unstructured":"Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science. 2000;289:1938\u201342.","journal-title":"Science"},{"key":"222_CR19","first-page":"256","volume":"11","author":"TL Tan","year":"2003","unstructured":"Tan TL, Yi ZS, Feng R. In vitro effect of STI571 on expression of c-kit in bone marrow cells from patients with acute non-lymphocytic leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2003;11:256\u20138.","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"222_CR20","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3109\/07853890109002093","volume":"33","author":"H Joensuu","year":"2001","unstructured":"Joensuu H, Dimitrijevic S. Tyrosine kinase inhibitor imatinib (STI571) as an anticancer agent for solid tumours. Ann Med. 2001;33:451\u20135.","journal-title":"Ann Med"},{"key":"222_CR21","doi-asserted-by":"crossref","first-page":"6151","DOI":"10.1093\/emboj\/16.20.6151","volume":"16","author":"T Skorski","year":"1997","unstructured":"Skorski T, Bellacosa A, Nieborowska-Skorska M, Majewski M, Martinez R, Choi JK, et al. Transformation of hematopoietic cells by BCR\/ABL requires activation of a PI-3k\/Akt-dependent pathway. EMBO J. 1997;16:6151\u201361.","journal-title":"EMBO J"},{"key":"222_CR22","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1182\/blood.V95.6.2118","volume":"95","author":"C Sillaber","year":"2000","unstructured":"Sillaber C, Gesbert F, Frank DA, Sattler M, Griffin JD. STAT5 activation contributes to growth and viability in Bcr\/Abl-transformed cells. Blood. 2000;95:2118\u201325.","journal-title":"Blood"},{"key":"222_CR23","first-page":"2049","volume":"60","author":"MW Deininger","year":"2000","unstructured":"Deininger MW, Vieira S, Mendiola R, Schultheis B, Goldman JM, Melo JV. BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia. Cancer Res. 2000;60:2049\u201355.","journal-title":"Cancer Res"},{"key":"222_CR24","first-page":"129","volume":"1072","author":"P Angel","year":"1991","unstructured":"Angel P, Karin M. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta. 1991;1072:129\u201357.","journal-title":"Biochim Biophys Acta"},{"key":"222_CR25","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/nrc1209","volume":"3","author":"R Eferl","year":"2003","unstructured":"Eferl R, Wagner EF. AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer. 2003;3:859\u201368.","journal-title":"Nat Rev Cancer"}],"container-title":["Tumor Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-011-0222-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13277-011-0222-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-011-0222-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T06:52:22Z","timestamp":1592895142000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13277-011-0222-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,3]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["222"],"URL":"https:\/\/doi.org\/10.1007\/s13277-011-0222-1","relation":{},"ISSN":["1010-4283","1423-0380"],"issn-type":[{"value":"1010-4283","type":"print"},{"value":"1423-0380","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,3]]}}}